Oestrogen-receptor status and endocrine therapy of breast cancer: response rates and status stability. by Leake, R. E. et al.
Br. J. Cancer (1981) 43, 59
OESTROGEN-RECEPTOR STATUS AND ENDOCRINE THERAPY
OF BREAST CANCER:
RESPONSE RATES AND STATUS STABILITY
R. E. LEAKE*, L. LAING*. K. C. CALMANt, F. R. MACBETH*t,
D. CRAWFORD: AND D. C. SMITH:
From, the Departments of*Biochenmistry and tOncology, Glasgow University
and the tDepartment ofSurgery, Victoria Infirmary, Glasgow
Received 8 AMay 1980 Accepte(l 30 September 1980
Summary.-The concentration of cellular oestrogen receptor (RE) was measured in
both the soluble and nuclear-pellet fractions of biopsies from 1,000 breast cancers.
Data suggest that functional steroid RE is always in equilibrium between the soluble
and nuclear fractions. However, biopsies from only one-third of patients contained
detectable amounts of high-affinity RE in both fractions. Thirty patients out of 42
(71%) whose biopsies contained RE in both fractions, showed objective remission
after receiving some form of hormonal manipulation as sole treatment. Response
rates in the other categories ranged from 9% for those whose biopsies contained no
detectable RE to 24% for those who displayed soluble RE alone. The presence of RE
in both fractions of primary disease was found to be an unreliable index of RE status
in subsequent secondary disease, whereas RE-negativity was maintained during
progression from primary to secondary disease. Other aspects of RE status in rela-
tion to stage ofdisease are analysed.
ENDOCRINE THERAPY is a long-estab-
lished treatment of secondary breast
cancer (Beatson, 1896). It is, however,
successful in only a small (, 25%) propor-
tion of cases (King & Roberts, 1979). The
choice of endocrine therapy for a particu-
lar patient has been made on the basis of
several clinical features, such as meno-
pausal status, disease-free interval, site of
dominant lesion, etc., and the response to
any earlier endocrine therapy (Pearson &
Ray, 1960; McGuire et al., 1977). The
absence of a single reliable index of hor-
mone dependence of breast tumours has
led to a marked decrease in recent years
of the use of ablative therapies.
Preliminary data from our laboratory
(Laing et al., 1977) have already indicated
that, in patients with advanced breast
cancer, response to endocrine therapy was
more likely when the tumour contained
oestrogen receptor RE in both the
soluble and pellet fractions. The same
data revealed the existence of oestrogen
receptor (REN) in the pellet, in the
absence of any soluble receptor (REC), a
previously unconsidered possibility. This
study also raised the question of the
existence of REN that was either unfilled
by steroid or, alternatively, bound to
chromatin in a manner which allowed the
steroid to dissociate at low temperatures.
The present paper reports both soluble
and pellet RE status for 1000 patients. It
then analyses the breakdown ofRE status
in relation to menopausal and nodal status
and to stage of disease. Responses to
endocrine therapy of 129 patients with
advanced disease in relation to RE status
is also reported.
Given the value of RE status as a tool
in determining therapy for secondary
Address for eorresponi(lecee: Dr R. E. Leake, Department of Bioclemistry, University of Glasgow,
Glasgow G12 8QQ.R. E. LEAKE ET AL.
disease, it would be very useful if such
status could be shown to reflect that in
primary disease. This would be particu-
larly valuable in cases in which secondary
disease is surgically inaccessible. Similarly,
the maintenance of RE status between
early (often local) and later recurrences is
also of considerable interest. RE status in
biopsies of both primary and secondary
disease is reported for 32 patients and
corresponding data between early and
later recurrence for 20 patients.
MATERIALS AND METHODS
Materials
3H-oestradiol-173 (sp. act. 44 mCi/,umol)
was obtained from The Radiochemical Centre,
Amersham, England.
All reagents were AnalaR grade.
Solutions were prepared in glass-distilled
water, since the presence of metal ions was
found to interfere with the assay of re-
ceptors.
Human breast tumour tissue was obtained
from 8 hospitals in the Glasgow area.
Methods
Tissue fractionation.-Tissue was collected
fresh and transported from the operating
theatre to the laboratory on ice. Wherever
possible, RE assay was performed the same
day, but, when this could not be achieved,
storage was at -20°C in sucrose buffer
(0-25M sucrose, 1-5mM MgCl2, 10mM Hepes,
pH 7.4)/50% glycerol (v:v) (Leake et al.,
1979). Soluble and nuclear fractions were then
prepared as follows.
About 150 mg of tissue was dissected from
the area adjacent to that removed for patho-
logical examination. Homogenization was
carried out at 50 mg/ml in 10mM Hepes,
1 5mM EDTA, 0-25mM DTT, pH 7-4 (HED
buffer) using 2 x 10s bursts at a setting of 150
on an Ultra-Turrax, model TP 18/2, followed
by further homogenization with a glass tissue
grinder (Kontes Duall). The homogenate was
centrifugated at 5000 g for 5 min at 4°C to
yield a "cytosol" supernatant and a crude
nuclear pellet. The pellet was washed x 3 in
0-15M NaCl, 10mM Hepes (pH 7.4), and finally
resuspended to the original volume in buffered
saline. A wash with 0.1% Triton X-100 was
on occasion incorporated at this stage to
further purify the nuclear material, but this
did not appreciably alter the level of nuclear
binding. Further purification of the pellet
fraction bydifferential centrifugation through
sucrose (finally 2f4M sucrose, 1 5mM MgC92)
did not significantly alter RE content ex-
pressed per unit DNA.
Assay of receptors.-The initial procedures
in the assay system were identical for both
tissue fractions. 1501p aliquots of cytosol or
nuclear suspension were added to 50u1l
aliquots of 3H-oestradiol-17/ to give final
concentrations of steroid of 1, 1-5, 2, 4, 6 and
8 x 10-10M. Two additional tubes were also
set up containing 10-9M 3H-oestradiol with
or without 10-7M unlabelled diethylstilbo-
estrol (DES) to determine the specificity of
binding. All tubes were then incubated at
4°C for 18 h. The inclusion of protease in-
hibitors Trasylol and/or phenylmethylsulph-
onyl fluoride (PMSF) in the incubation
medium did not appear to enhance RE
measurement. After incubation, the amount
of steroid bound was determined for each
fraction as follows.
Cytosol receptors (REc).-At the end of the
incubation period, 0-9 ml of 1 5mM EDTA,
10mM Hepes (pH 7.4) and 0 5 ml Dextran-
coated charcoal (0X15% (w:v) charcoal and
0-0015% (w: v) dextran T-70, equilibrated in
025M sucrose, 1 5mM EDTA, 10mM Hepes,
pH 7.4) were added to each tube. This mix-
ture was agitated at 0°C for 15 min followed
by centrifugation at 1000 g for 5 min. To lml
aliquots of each supernatant was added
10 ml Triton-toluene scintillant (200 ml
ethanol: 600 ml Triton X-100: 1400 ml
toluene/PPO (5 g/l)/POPOP (0-24 g/l)) and
each counted at 25% efficiency in a Philips
or at 30% in a Searle Mark III Liquid Scin-
tillation analyser.
Nuclear receptors (REN).-Following in-
cubation, 1001ul aliquots were removed from
each tube and added to 5ml saline. This mix-
ture was poured down the chimney of a
Millipore filter apparatus on to a pre-wetted
Whatman GF/C glass-fibre filter. The tube
was washed out with 5 ml saline, the washing
poured on to the filter and the filter further
washed with 3 x 4 ml saline under suction.
After removal ofthe chimney, the edge ofthe
filter was washed and the filter removed into
a scintillation vial prior to drying overnight
at 60°C. 10 ml toluene/PPO (5 g/l) scintillant
was added, and the samples counted at 35%
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efficiency in a Philips or Searle Mark III
Liquid Scintillation analyser.
Protein and DNA assay.-Cytosol protein
concentration was determined by the method
ofLowry.
DNA content was determined by a modi-
fication of the method of Burton (1956) as
described by Katzenellenbogen & Leake
(1974).
Definition ofpositivity
To be classed as RE+ the binding displayed
by either tissue fraction was required to fulfil
3 criteria: (a) yield anunambiguous Scatchard
plot, which produces (b) a straight line,
giving a Kd in the range 0 5-5 x 10-10M;
(c) specificity must be established by com-
petition with excess diethylstilboestrol. RE
concentrations as low as 3 fmol/mg protein
and 25 fmol/mg DNA were detected for the
soluble and pellet fractions respectively.
Response to hormone therapy was assessed
in patients with secondary disease for whom
(a) RE status had been determined before the
initiation of any therapy, (b) endocrine
therapy alone was applied as first treatment
during the period of assessment. The criteria
for response were those suggested by the
British Breast Group (1974). In brief, these
involve at least 50% regression of existing
lesions, and no appearance of new lesions
within a 6-month period. Only patients
satisfying these criteria for at least 6 months
are recorded as having responded (Table
VII).
RESULTS
Primary disease
The distribution of patients by RE
status is shown in Table I. This is a com-
pilation of data from pre- or post-meno-
pausal patients with primary disease.
Patients with RE in both soluble and
pellet fractions are classified as ( + + ),
those with only REC as (+ /0), those with
only REN as (0/ + ) and those with RE in
neither fraction as (0/0).
Tumours with functional oestrogen RE
would be expected to display both REc
and REN, even at very high plasma
oestrogen levels, since an equilibrium is
always maintained between filled receptor
in the 2 pools (Williams & Gorski, 1971;
TABLE I.-Analysis of cytoplasmic and
nuclear oestrogen receptors in 1000
biopsies of breast tumour tissue
Receptor
content
REc/REN
+I+
O /0
+/0
0/+
No.
patients
343
479
118
60
34
48
12
6
Sheridan et al., 1979). Patients in the +/+
category would, therefore, be expected to
have hormone-sensitive tumours, whereas
all other categories of tumour might be
expected to be autonomous, or respond to
endocrine therapy only by an indirect
route.
When RE status of patients is re-
analysed in relation to menopausal status
(Table II) it is seen that the proportions
TABLE II.-Distribution of oestrogen re-
ceptors between the cytoplasmic and
nuclear fractions of breast tumour tissue
from pre- and post-menopausal patients
Premenopausal
REC/REN No. patients (%)
+/+ 22 (32)
0/0 34 (50)
+/0 12 (18)
0/+ 0 (0)
Postmenopausal
No. patients (%)
69 (36)
81((42)
26 (13)
17 (9)
in each of the categories (1) functional
RE+, (2) RE- and (3) REC alone remain
fairly similar. However, the small group of
tumours which contain only REN appears
to be confined to post-menopausal
patients. This suggests either an abnor-
mality in RE function associated with
menopause or a failure to exchange
oestrogen on to this class ofreceptor in the
pre-menopausal nuclear samples under
the conditions used. Since the REN in
+/ + samples of premenopausal patients
clearly does exchange oestrogen, the latter
suggestion is perhaps less likely.
Analysis of RE status of primary
disease in relation to stage of disease is
shown in Table III. The number of
patients involved in each individual cate-
gory is fairly small. There is no significant
difference in the stage of the disease at
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TABLE III.-Comparison of RE status and
clinical stage in biopsies of 191 primary
breast cancers
No. patients in each stage
REC/REN I II III IV
+/+ 26 27 5 1
0/0 38 55 6 4
+/O 7 7 0 1
O/+ 6 8 0 0
first presentation when biopsies are classi-
fied as containing functional RE (+/+)
or completely lacking in REc (0/0). This
is, perhaps, surprising in view of the con-
cept that absence of RE indicates a more
rapidly progressing tumour (Meyer et al.,
1977).
The distribution of RE was also re-
analysed in relation to nodal status. It
was thought that patients with RE-
tumours would be more likely to exhibit
nodal involvement than those with RE+
disease. However, the data in Table IV do
TABLE IV.-Comparison of RE status and
nodal status in 134 breast tumour biopsies
No. patients
REc/REN Node -ve (%) Node +ve (%)
+/+ 20 (49) 21 (51)
0/0 26 (40) 39 (60)
+/O 5 (33) 10 (67)
0/+ 8 (62) 5 (38)
not support this idea. The potential for
nodal infiltration is clearly not dependent
on receptor status. This observation
agreed with that of Hahnel et al. (1979)
although a loose relationship between
nodal involvement and RE-negativity
was reported by Allegra et al. (1979).
Receptor status stability
Much of the early interest in RE status
was derived from the idea that measure-
ments on biopsies of primary disease
would act as reliable therapeutic indices
once secondary growth was detected
(King, 1975; Jensen, 1975). However,
practical demonstration of the stability of
RE status between biopsy and the appear-
TABLE V.-REc andREN status in biopsies
of primary and secondary breast disease
from the same patient
Patient Age
517535 59
529941 41
490197 64
543284 58
206073 40
335662 56
554902 78
517288 59
512434 44
338381 52
190658 unknown
533839 38
550668 43
559665 64
528446 68
528171 68
297738 46
519488 49
420564 52
348637 57
525191 77
498101 43
227746 75
551907 64
263806 80
526290 44
341527 52
518777 49
297515 71
305543 67
409965 46
653306 unknown
Months
between
biopsies
34
11
19
19
10
17
8
8
14
21
13
21
31
7
16
2
11
12
21
5
12
6
23
12
4
19
5
23
18
15
32
23
RE C/REN status
Primary Secondary
0/0 0/0
0/0 0/0
+/+ +/+
0/0 0/0
0/0 0/0
+/+ 0/0
0/+ +/0
+/+ +1+
0/0 0/0
+/0 0/+
+/0 0/
0/0 0/0
0/0 0/+
+/0 0/0
+/+ +1+
0/0 0/0
0/0 0/0
0/0 0/0
0/0 +/+
0/0 0/0
0/0 0/0
0/0 0/0
0/0 0/0
+/+ +/+
0/0 0/0
+/+ +/0
0/0 0/0
+1+ 0/0
+/+ +/0
0/+ +/0
+/+ +/+ +1+ 01+
ance ofsecondary disease has been limited
due to the difficulties in (a) maintaining a
stable patient population and (b) obtain-
ing sufficient material from the metastatic
site. Table V shows RE status determined
in primary and subsequent secondary
disease from 32 patients. None of the
patients received known relevant therapy
in the intervening period. In 20 cases
(63%) RE status is the same for both
biopsies. Only 5/10 receptor-positive cases
remained +/+ indicating that hormone
dependence in primary disease is not
necessarily retained in secondary disease.
Only one out of 17 RE- patients (0/0)
developed RE+ + ( + ) secondary growth.
Both tamofixen (Leake et al., 1979) and
chemotherapy have been found to either
block RE synthesis or interfere with the
RE assay, but this patient had received
no such relevant therapy prior to biopsy.
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Thus a RE- primary is almost certain to
give rise to hormone insensitive secondary
disease.
When RE status is compared between
first occurrence and later recurrences
(Table VI) it is again clear that 0/0
disease generally retains this status. Of 12
biopsies examined, only one changed
status. Once more, it was striking that
change of status was common in biopsies
with RE in only one fraction. Ofthe RE+
biopsies obtained in early recurrence, 3/4
retained functional RE (+/+).
Further examination of the group of
patients whose biopsies had REC alone
was carried out. It was apparent (Figure)
that the RE concentration in tissues with
REc alone (+ /0) wasrelatively lower than
that in RE+ (+/+) biopsies. However, a
significant number of biopsies (11/118) in
this category (+/0) had receptor concen-
trations in excess of 100 fmol/mg protein.
Thus, although there is an indication that
high REc concentration is equivalent to a
TABLE VI.-REc and REN status in
biopsies of more than one secondary
deposit from the same breast-cancer
patient
Age at Months
first between
biopsy biopsies
41 2
48 13-& 9
58 4
unknown 23
59 14 & 10
47 18
unknown 6
60 14
46 6
64 10
49 7
52 1
49 11, 12&2
77 7
unknown 10
72 25
unknown 14
44 10
49 3
45 30
REc/REN
,
I
1st
sample
0/0
0/0
0/0
+/0
+I+
0/0
0/+
0/0
0/0
0/0
0/0
+I+
+/0
0/0
0/0
0/0
+/0
0/0
2nd 3rd
sample sample
0/0
0/0 0/0
0/0 -
0/0 -
+/+ 0/0*
0/0 -
0/0
0/0 -
0/0
0/0 +/+t
0/0
0/0
0/0
0/0 -
0/0
* Patient withdrawn from tamoxifen only 10 days
previously (see text).
t Fourth biopsy-0/0.
5
1. 10 11 20 21- 30 31 40 41-50 51 60 61 70 71-80 81-90 91-100 > 1lO
REc (tsolAmg cytosd protein)
FIGURE.-The concentration of soluble RE
in biopsies from patients with functional
RE (+/+, ED) and those with RE only
in the soluble fraction (+/0, *). The
total number of biopsies in each of the two
categories (118) was identical.
good chance of response to endocrine
therapy, no absolute rule applies.
Endocrine therapy of advanced disease
All patients with advanced disease for
whom the RE status of an appropriate
biopsy was known, were monitored
throughout subsequent treatment. The
response of those patients who received
any type of hormonal therapy as first-line
treatment for any period was noted in
relation to the criteria listed earlier. The
results are summarized in Table VII.
Patients whose biopsies showed an intact
RE system had a very good chance of
responding to some type of endocrine
therapy (most commonly tamoxifen treat-
ment). Only 5 patients (9%) of those in
the truly RE- class showed good response.
In each case these patients had received
tamoxifen, and may have responded to
one of the actions of this drug which is
not RE-mediated (Tisdale, 1977). It is
TABLE VII.-Response of breast tumours to
hormone therapy in relation to their RE
content
REC/REN
0/0
+/O
o/ +
Total patients
45
58
17
9
Complete
response (%)
32 (71)
5 (9)
4 (24)
1 (11)
Patient
529941
503664
543284
612828
517288
576240
190658
416889
297738
560179
519488
420564
482442
525191
249687
170263
AF/V
526290
518777
544403
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striking that the patients whose biopsies
contained RE in only one fraction (0/+
or +/0) behaved in a manner similar to
the RE- group, suggesting that these re-
ceptors are non-functional, though there
is no indication whether the fault lies in
the RE itself or in some cellular recogni-
tion site.
Of the patients in Table VII, those who
did not experience a complete response for
6 months were divided as follows: in the
( + / + ) category 8 had progressive disease,
1 was static and 3 showed a partial re-
sponse; in the (0/0) category 48 had pro-
gressive disease, 3 were static and 2
showed a partial response; in the (+/0)
category 10 had progressive disease, 1 was
static and 2 showed partial response; in
the (0/ + ) category all 8 patients had pro-
gressive disease. Of the 129 patients con-
sidered, only 27 were pre-menopausal and
10 menopausal. The response rates quoted,
therefore, apply principally to post-meno-
pausal disease. It is, however, significant
that 18/27 pre-menopausal patients had
both biopsies with no detectable RE (0/0)
and suffered progressive disease. Of the 42
patients experiencing complete response,
18 had local recurrence, 10 had recurrence
in gland and/or skin, 7 in bone and the
remainder at one or more distant sites. Of
74 patients with progressive disease, 13
had local recurrence, 21 skin and/or gland,
21 bone, 7 pleura, 7 liver andthe remainder
at one or more distant sites.
DISCUSSION
Both established dogma (Leake, 1976)
and recent interpretations (Sheridan et al.,
1979) ofsteroid hormone action essentially
require that functional hormone RE com-
plex forms an equilibrium between the
soluble and nuclear-pellet fractions of the
cell. Such an equilibrium is rapidly estab-
lished at 37°C, but can also be established
at 0°C over 22 h (Traish et al., 1979).
Similarly, the distribution of RE between
the soluble and nuclear-pellet fractions of
target tissue has also been successfully
measured at both 37°C and 4°C by use of
different incubation times, though the
decreased stability of receptor at 37°C in
the cell-free environment meant that assay
at 4°C (or 20°C) gave more reproducible
results (Leake et al., 1979). Thus, hormonal
dependence of a particular human breast
tumour biopsy should be reflected in the
presence of measurable quantities of RE
in both soluble and pellet fractions of said
biopsy.
After adopting strict criteria for the
measurement of cellular RE (Leake et al.,
1979) it was found that only one-third of
patients with primary disease yielded
biopsies containing functional RE (Table
I), i.e. RE in both soluble and pellet frac-
tions. Biopsies from about half the
patients had undetectable levels of high-
affinity RE. This is a surprisingly large
proportion, but has been maintained
throughout the study. Further, the low
rate of response of advanced disease to
hormone therapy in patients lacking RE
(Table VII), taken together with the
observation that RE- (0/0) primaries give
rise to RE- secondaries (Table V), suggest
that such a high incidence of hormonal
insensitivity is real. The 2 initially
unexpected groups of patients (+/0) and
(0/ + ) (Laing et al., 1977) continue to pre-
sent. Such patients with RE in one frac-
tion ofthe biopsy only have now also been
observed in other studies (Panko &
MacLeod, 1978; Thorsen, 1979; Barnes et
al., 1979).
Much of the value of determining RE
status in primary disease depends upon
the assumption that in subsequent secon-
dary disease RE status will faithfully
reflect that in the primary biopsy. How-
ever, in a study of 32 patients for whom
RE status was determined in both primary
and advanced disease (Table V), only half
the primaries with fully functional RE
gave rise to ( + / + ) secondaries. This is a
disappointingly low level of consistency of
RE status between primary and secondary
disease, but may reflect the fact that the
secondary samples are necessarily selected
from surgically accessible sites. The con-
sistency of RE status might be higher if
all sites of secondary disease were con-
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sidered. These patients had received no
adjuvant therapy, so the loss of RE must
have resulted during the natural progres-
sion ofthe disease. Further studies in pro-
gress may clarify this situation.
It was more encouraging to find that
RE status in only 1 patient out of 17
reverted from RE- primary to fully RE+.
Patients whose receptors fell in the
abnormal categories (+/0 or 0/ +) were
found to show a high level of variation
between primary and secondary disease.
However, there were no cases ofchange to
RE+ status. Hence patients whose pri-
maries are either RE- or abnormal have
very little chance ofsubsequently respond-
ing to hormonal manipulation.
The follow-up data in Table VII show
that patients whose biopsies of secondary
disease contain fully functional RE have a
much better chance of objective response
to human manipulation than do those
with either no RE or RE in one fraction
only. The criteria of clinical response used
in this paper are quite severe (British
Breast Group, 1974) similar to those pro-
posed by the UICC (Hayward et al., 1977).
Stoll (1977) proposed shorter periods of
sustained response. Adoption of less
stringent criteria will increase the response
rate in any series. However, no biological
index is ever likely to identify potential
responders with complete accuracy, since
so many variables are involved. Alterna-
tive indices of hormonal-dependence have
been tried, and perhaps the most success-
ful is measurement ofsoluble progesterone
receptor, a product of oestrogen action in
normal target tissue. Recent studies by
Barnes et al. (1979), Thorsen & Stoa (1979)
and in our own laboratory suggest that
although the presence of RP is not always
associated with an improved clinical
response, it is usually associated with the
presence of fully functional RE and so
yields a similar success rate in the identifi-
cation of responders to hormone therapy.
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